Clinical Trial

Pancreatic Enzyme Replacement in Acute Necrotizing Pancreatitis

Study acronym: PERiANP
Recruiting Phase 3
View on ClinicalTrials.gov →
Summary
In this multicenter, double blinded, placebo-controlled, 1:1 parallel group RCT, the investigators propose to evaluate the impact of pancreatic exocrine replacement therapy on patients with acute necrotizing pancreatitis (ANP). The investigators will include patients of 18-60yrs age and both genders with \>50% pancreatic parenchymal necrosis and at least 5% loss of body weight. The primary outcome measure is percent change in body weight at 3 months after enrolment. The intervention will include pancreatic enzyme consisting of 25000 IU of lipase and similar appearing placebo.
Protocol Amendment History 2 changes
critical Recruitment opened 2026-05-06
notable Trial sites expanded: 1 -> 4 locations 2026-05-06
Trial Details
NCT Number NCT07441824
Lead Sponsor Asian Institute of Gastroenterology, India
Conditions Acute Necrotizing Pancreatitis, Pancreatic Exocrine Insufficiency
Enrollment 140 participants
Start Date 2026-04-10
Primary Completion 2027-06 (estimated)
Study Completion 2027-06 (estimated)
Updated on ClinicalTrials.gov 2026-05-05